• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    National Vision Holdings, Inc. Reports Third Quarter 2024 Financial Results

    11/6/24 6:00:00 AM ET
    $EYE
    Ophthalmic Goods
    Health Care
    Get the next $EYE alert in real time by email

    Results Reflect Ongoing Strength in Managed Care with Growth in America's Best as Transformation Initiatives Progress

    Third quarter 2024 highlights compared to Q3 2023:

    • Net revenue from continuing operations of $451.5 million, an increase of 2.9%
    • Comparable store sales growth of 1.4% and Adjusted Comparable Store Sales Growth of 0.9%
    • Net loss from continuing operations of $(8.4) million, Diluted EPS from continuing operations of $(0.11)
    • Adjusted Operating Income from continuing operations of $14.3 million
    • Adjusted Diluted EPS from continuing operations of $0.12
    • Reaffirms fiscal 2024 outlook for key metrics, updates capital expenditure expectations

    National Vision Holdings, Inc. (NASDAQ:EYE) ("National Vision" or the "Company") today reported its financial results for the third quarter ended September 28, 2024.

    "We are encouraged by the progress we are making against key elements of our transformation, including completing the review of our store fleet, implementing new traffic-driving initiatives, continuing to expand exam capacity and remote exam efficiency, and benefiting from new perspectives through our deepened executive bench," said Reade Fahs, National Vision's CEO. "During the quarter, we experienced top line trends consistent with prior quarters as America's Best continued to drive our sales performance supported by strength in our managed care business. In addition, customers responded well to our new Wise Buys eyeglass promotion that helped to enhance our value offering and attract new customers. We continued to leverage our remote capabilities to expand exam capacity as well as provide doctors with convenient new ways to practice. While we continue to execute on our transformation, we are pleased to reiterate our guidance for the year and remain committed to positioning National Vision for long term success."

    This release includes certain Non-GAAP Financial Measures that are not recognized under generally accepted accounting principles ("GAAP"). Please see "Non-GAAP Financial Measures" and "Reconciliation of Non-GAAP to GAAP Financial Measures" below for more information.

    During the first nine months of fiscal 2024, the Company ceased its Walmart and AC Lens operations and, accordingly, the condensed consolidated financial statements reflect the results of the Legacy segment and the substantial majority of AC Lens operations as discontinued operations for all periods presented. Unless otherwise noted, amounts and disclosures below relate to the Company's continuing operations.

    Third Quarter 2024 Summary

    • Net revenue increased 2.9% to $451.5 million compared to the third quarter of 2023 and was primarily driven by growth from new store sales and Adjusted Comparable Store Sales Growth and the effect of unearned revenue, partially offset by the effect of converted and closed stores and lower e-commerce revenue. Net revenue includes a positive 0.4% impact from the timing of unearned revenue in the current-year period compared with the prior-year period.
    • Comparable store sales growth was 1.4% and Adjusted Comparable Store Sales Growth was 0.9%, both reflecting a higher average ticket and an increase in customer transactions.
    • The Company opened 18 new stores and closed two America's Best and one Military store as a result of the host partner's decision to cease its overall operations at the location, and ended the quarter with 1,231 stores. Overall, store count grew 4.9% from September 30, 2023 to September 28, 2024.
    • Costs applicable to revenue increased 3.3% to $189.9 million compared to the third quarter of 2023. As a percentage of net revenue, costs applicable to revenue increased 20 basis points to 42.1% compared with the third quarter of 2023 and were primarily driven by an increase in optometrist-related costs as well as other mix and margin effects. As a percentage of net revenue, these increased costs were partially offset by higher exam revenue.
    • Selling, general and administrative expenses (SG&A) increased 2.8% to $234.0 million compared with the third quarter of 2023. Adjusted SG&A increased 1.7% to 225.0 million compared with the third quarter of 2023. As a percentage of net revenue, SG&A was 51.8%, comparable to the third quarter of 2023, driven by lower performance-based incentive compensation, offset by higher payroll expense and other operating expenses, including higher IT investments and occupancy expense. As a percentage of net revenue, Adjusted SG&A decreased 60 basis points to 49.8% compared with the third quarter of 2023, driven by lower performance-based incentive compensation and other operating expenses, partially offset by higher payroll and occupancy expenses.
    • Depreciation and amortization expense of $22.7 million increased 1.0% from the prior-year period, primarily driven by investments in remote medicine technology and new store openings, partially offset by lower depreciation of labs and distribution center.
    • Income (loss) from continuing operations, net of tax, decreased to $(8.4) million, compared to $(0.4) million in the third quarter of 2023. Income (loss) from continuing operations, net of tax, margin was (1.9)% compared to (0.1)% in the third quarter of 2023.
    • Diluted earnings (loss) per share (EPS) from continuing operations decreased to $(0.11), compared to $(0.00) in the third quarter of 2023. Adjusted Diluted EPS was $0.12 compared with $0.11 in the third quarter of 2023. The net change in margin on unearned revenue benefited both Diluted EPS and Adjusted Diluted EPS by $0.01.
    • Adjusted Operating Income increased 22.2% to $14.3 million compared with the third quarter of 2023. Adjusted Operating Margin was 3.2% for the third quarter of 2024 compared to 2.7% for the third quarter of 2023. The net change in margin on unearned revenue benefited income (loss) from continuing operations, net of tax, by $0.9 million and Adjusted Operating Income by $1.2 million.

    Year-to-Date 2024 Summary

    • Net revenue increased 3.8% to $1,386.0 million compared to the prior-year period and was primarily driven by growth from new store sales, Adjusted Comparable Store Sales Growth and the effect of unearned revenue, partially offset by the effect of converted and closed stores and lower e-commerce revenue. Net revenue includes a positive 0.3% impact from the timing of unearned revenue in the current-year period compared with the prior-year period.
    • Comparable store sales growth was 1.7% and Adjusted Comparable Store Sales Growth was 1.2%, primarily due to higher average ticket and an increase in customer transactions.
    • The Company opened 49 new stores, closed four America's Best stores, one Eyeglass World store, and one Military store as a result of the host partner's decision to cease its overall operations and converted 20 Eyeglass World stores to America's Best stores, and ended the period with 1,231 stores. Overall, store count grew 4.9% from September 30, 2023 to September 28, 2024.
    • Costs applicable to revenue increased 5.2% to $579.1 million compared to the prior-year period. As a percentage of net revenue, compared with the prior-year period, costs applicable to revenue increased 60 basis points to 41.8%, mainly due to an increase in optometrist-related costs, lower eyeglass mix and other mix and margin effects. As a percentage of revenue, these increased costs were partially offset by higher exam revenue.
    • SG&A increased 3.9% to $705.5 million compared with the same period in 2023. Adjusted SG&A increased 2.1% to $677.3 million compared with the same period in 2023. As a percentage of net revenue, SG&A was 50.9%, comparable to the same period of 2023, mainly due to litigation settlement, occupancy and legal and professional expenses, offset by decreases in performance-based incentive compensation. As a percentage of net revenue, Adjusted SG&A decreased 80 basis points driven by a decrease in performance-based incentive compensation and other operating expenses, partially offset by higher occupancy expense.
    • Depreciation and amortization expense of $68.6 million increased 3.1% from the prior-year period, primarily driven by new store openings and investments in remote medicine technology, partially offset by lower depreciation of labs and distribution center.
    • Income from continuing operations, net of tax, decreased to $2.3 million compared to $18.3 million in the same period in 2023. Income from continuing operations, net of tax, margin decreased to 0.2% compared to 1.4% in the same period in 2023.
    • Diluted EPS from continuing operations was $0.03 compared to $0.23 in the same period in 2023. Adjusted Diluted EPS increased to $0.56 compared to $0.51 in the same period in 2023. The net change in margin on unearned revenue benefited both Diluted EPS and Adjusted Diluted EPS by $0.03.
    • Adjusted Operating Income increased 9.9% to $62.3 million compared with the same period of 2023. Adjusted Operating Margin was 4.5% compared with 4.2% for the same period in 2023. The net change in margin on unearned revenue benefited income (loss) from continuing operations, net of tax, by $2.6 million and Adjusted Operating Income by $3.4 million.

    Balance Sheet and Cash Flow Highlights as of September 28, 2024

    • National Vision's cash balance was $81.2 million as of September 28, 2024. The Company had no borrowings under its $300.0 million first lien revolving credit facility, exclusive of letters of credit of $6.4 million.
    • Repurchased $218 million of 2025 Notes for an aggregate cash purchase price of $215 million. Funded with $115 million of incremental term loans and $100 million of cash.
    • Total debt was $353.8 million as of September 28, 2024, consisting of outstanding first lien term loans, 2.50% convertible senior notes due on May 15, 2025 ("2025 Notes") and finance lease obligations, net of unamortized discounts.
    • Cash flows from operating activities for the first nine months of 2024 were $103.4 million compared to $153.3 million for the same period in 2023.
    • Capital expenditures for the first nine months of 2024 totaled $63.5 million compared to $82.0 million for the same period in 2023.

    Provides Update on Portfolio Review and Fiscal 2025 New Store Opening Plan

    Today, the Company issued a press release announcing the completion of its comprehensive store fleet review and actions to address identified stores. The Company also announced that it plans to open 30 to 35 new stores in Fiscal 2025 and invest capital in existing operations to enhance the overall store experience. The press release is available on the Company's website.

    Fiscal 2024 Outlook

    National Vision's fiscal 2024 outlook reflects current expected or estimated impacts related to macro-economic factors, including inflation, geopolitical instability and risks of recession, as well as constraints on exam capacity and the Company's transformation initiatives; however, the ultimate impact of these factors on the Company's financial outlook remains uncertain with dynamic market conditions and the outlook shown below assumes no material deterioration to the Company's current business operations as a result of such factors or as a result of the termination of the Walmart partnership. Unless otherwise noted, the outlook below is on a continuing operations basis.

    The Company reaffirms the previously provided outlook for its key operating metrics, while updating its expectations for capital expenditures. The Company is providing the following outlook for the 52 weeks ending December 28, 2024:

     

    Continuing Operations Fiscal 2024 Outlook

    New Stores

    65-70

    Adjusted Comparable Store Sales Growth1

    0.5% - 1.5%

    Net Revenue (billions)

    $1.820 - $1.840

    Adjusted Operating Income (millions)

    $57 - $62

    Adjusted Diluted EPS2

    $0.45 - $0.50

    Depreciation and Amortization3 (millions)

    $94 - $99

    Interest4 (millions)

    $7 - $9

    Tax Rate5

    26% to 28%

     

    Prior Capital Expenditures

    Outlook (as of August 7, 2024)

    Current Capital Expenditures

    Outlook

    Capital Expenditures (millions)

    $110 - $115

    $100 - $105

    1 Refer to the Reconciliation of Adjusted Comparable Stores Sales Growth to Total Comparable Store Sales Growth.

    2 Assumes approximately 79 million shares, and does not include 2.7 million shares attributable to the 2025 Notes as the Company anticipates them to be anti-dilutive to earnings per share for fiscal year 2024.

    3 Includes amortization of acquisition intangibles of approximately $1.3 million for continuing operations, which is excluded in the definition of Adjusted Operating Income.

    4 Before the impact of gains or losses on change in fair value of derivatives and charges related to debt discounts and deferred financing costs.

    5 Excluding the impact of vesting of restricted stock units and stock option exercises.

    The fiscal 2024 outlook information provided above includes Adjusted Operating Income and Adjusted Diluted EPS guidance, which are non-GAAP financial measures management uses in measuring performance. The Company is not able to reconcile these forward-looking non-GAAP measures to comparable GAAP measures without unreasonable efforts because it is not possible to predict with a reasonable degree of certainty the actual impact of certain items and unanticipated events, including taxes and non-recurring items, which would be included in GAAP results. The impact of such items and unanticipated events could be potentially significant.

    The fiscal 2024 outlook is forward-looking, subject to significant business, economic, regulatory and competitive uncertainties and contingencies, many of which are beyond the control of the Company and its management, and based upon assumptions with respect to future decisions, which are subject to change. Actual results may vary and those variations may be material. As such, the Company's results may not fall within the ranges contained in its fiscal 2024 outlook. The Company uses these forward-looking measures internally to assess and benchmark its results and strategic plans. See "Forward-Looking Statements" below.

    Conference Call Details

    The Company will host a conference call to discuss the third quarter 2024 financial results and fiscal-year 2024 guidance today, November 6, 2024, at 8:30 a.m. Eastern Time. To pre-register for the conference call and obtain a dial-in number and passcode please refer to the "Investors" section of the Company's website at www.nationalvision.com/investors. A live audio webcast of the conference call will be available on the "Investors" section of the Company's website at www.nationalvision.com/investors, where presentation materials will be posted prior to the conference call. A replay of the audio webcast will also be archived on the "Investors" section of the Company's website.

    About National Vision Holdings, Inc.

    National Vision Holdings, Inc. (NASDAQ:EYE) is one of the largest optical retail companies in the United States with over 1,200 stores in 38 states and Puerto Rico. With a mission of helping people by making quality eye care and eyewear more affordable and accessible, the company operates four retail brands: America's Best Contacts & Eyeglasses, Eyeglass World, and Vista Opticals inside select Fred Meyer stores and on select military bases, and an e-commerce website DiscountContacts.com, offering a variety of products and services for customers' eye care needs. For more information, please visit www.nationalvision.com.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934. These statements include, but are not limited to, statements contained under "Fiscal 2024 Outlook," as well as other statements related to our current beliefs and expectations regarding the performance of our industry, the Company's strategic direction, market position, prospects including remote medicine and optometrist recruiting and retention initiatives, and future results. You can identify these forward-looking statements by the use of words such as "outlook," "guidance," "believes," "expects," "potential," "continues," "may," "will," "should," "could," "seeks," "projects," "predicts," "intends," "plans," "estimates," "anticipates" or the negative version of these words or other comparable words. Caution should be taken not to place undue reliance on any forward-looking statement as such statements speak only as of the date when made. We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.

    Forward-looking statements are not guarantees and are subject to various risks and uncertainties, which may cause actual results to differ materially from those implied in forward-looking statements. Such factors include, but are not limited to, the termination of our partnership with Walmart, including the transition period and other wind down activities, will have an impact on our business, revenues, profitability and cash flows, which impact could be material; market volatility, an overall decline in the health of the economy and other factors impacting consumer spending, including inflation, uncertainty in financial markets, recessionary conditions, escalated interest rates, the timing and issuance of tax refunds, governmental instability, war and natural disasters, may affect consumer purchases, which could reduce demand for our products and materially harm our sales, profitability and financial condition; failure to recruit and retain vision care professionals for in-store roles or to provide remote care offerings could adversely affect our business, financial condition and results of operations; the optical retail industry is highly competitive, and if we do not compete successfully, our business may be adversely impacted; if we fail to open and operate new stores (including as a result of store conversions) in a timely and cost-effective manner or fail to successfully enter new markets, our financial performance could be materially and adversely affected; if the performance of our Host brands declines or we are unable to maintain or extend our operating relationships with our Host partners, our business, profitability and cash flows may be adversely affected and we may be required to incur impairment charges; we are a low-cost provider and our business model relies on the low-cost of inputs and factors such as wage rate increases, inflation, cost increases, increases in the price of raw materials and energy prices could have a material adverse effect on our business, financial condition and results of operations; we require significant capital to fund our expanding business, including updating our Enterprise Resource Planning ("ERP") and Customer Relationship Management ("CRM"), and other technological, systems and capabilities; our ability to successfully implement transformation initiatives (including store fleet optimization); our growth strategy could strain our existing resources and cause the performance of our existing stores to suffer; our success depends upon our marketing, advertising and promotional efforts and if we are unable to implement them successfully or efficiently, or if our competitors are more effective than we are, we may experience a material adverse effect on our business, financial condition and results of operations; we are subject to risks associated with leasing substantial amounts of space, including future increases in occupancy costs; certain technological advances, greater availability of, or increased consumer preferences for, vision correction alternatives to prescription eyeglasses or contact lenses, or future drug development for the correction of vision-related problems may reduce the demand for our products and adversely impact our business and profitability; if we fail to retain our existing senior management team or attract qualified new personnel such failure could have a material adverse effect on our business, financial condition and results of operations; our profitability and cash flows may be negatively affected if we are not successful in managing our inventory balances and inventory shrinkage; our operating results and inventory levels fluctuate on a seasonal basis; our e-commerce and omni-channel business faces distinct risks, and our failure to successfully manage those risks could have a negative impact on our profitability; we depend on our distribution centers and/or optical laboratories; we may incur losses arising from our investments in technological innovators in the optical retail industry, including artificial intelligence, which would negatively affect our financial results; environmental, social and governance ("ESG") issues, including those related to climate change, could have a material adverse effect on our business, financial condition and results of operations; changing climate and weather patterns leading to severe weather and disasters may cause significant business interruptions and expenditures; future operational success depends on our ability to develop, maintain and extend relationships with managed vision care companies, vision insurance providers and other third-party payors; we face risks associated with vendors from whom our products are sourced and are dependent on a limited number of suppliers; we rely heavily on our information technology systems, as well as those of our vendors, for our business to effectively operate and to safeguard confidential information; any significant failure, inadequacy, interruption or security breach could adversely affect our business, financial condition and operations; we rely on third-party coverage and reimbursement, including government programs, for an increasing portion of our revenues, the future reduction of which could adversely affect our results of operations; we are subject to extensive state, local and federal vision care and healthcare laws and regulations and failure to adhere to such laws and regulations would adversely affect our business; we are subject to managed vision care laws and regulations; we are subject to rapidly changing and increasingly stringent laws, regulations, contractual obligations, and industry standards relating to privacy, data security and data protection which could subject us to liabilities that adversely affect our business, operations and financial performance; we could be adversely affected by product liability, product recall or personal injury issues; failure to comply with laws, regulations and enforcement activities or changes in statutory, regulatory, accounting and other legal requirements could potentially impact our operating and financial results; adverse judgments or settlements resulting from legal proceedings relating to our business operations could materially adversely affect our business, financial condition and results of operations; we may not be able to adequately protect our intellectual property, which could harm the value of our brand and adversely affect our business; we have a significant amount of indebtedness which could adversely affect our business and financial position, including limiting our business flexibility and preventing us from meeting our debt obligations; a change in interest rates may adversely affect our business; our credit agreement contains restrictions that limit our flexibility in operating our business; conversion of the 2025 Notes could dilute the ownership interest of existing stockholders or may otherwise depress the price of our common stock; and risks related to owning our common stock, including our ability to comply with requirements to design and implement and maintain effective internal controls. Additional information about these and other factors that could cause National Vision's results to differ materially from those described in the forward-looking statements can be found in filings by National Vision with the Securities and Exchange Commission ("SEC"), including our latest Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, which are accessible on the SEC's website at www.sec.gov. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this release and in our filings with the SEC.

    Non-GAAP Financial Measures

    To supplement the Company's financial information presented in accordance with GAAP and aid understanding of the Company's business performance, the Company uses certain non-GAAP financial measures, namely "EBITDA," "Adjusted Operating Income," "Adjusted Operating Margin," "Adjusted EBITDA," "Adjusted EBITDA Margin," "Adjusted Diluted EPS," "Adjusted Comparable Stores Sales Growth," "Adjusted SG&A," and "Adjusted SG&A Percent of Net Revenue." We believe EBITDA, Adjusted Operating Income, Adjusted Operating Margin, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Diluted EPS, Adjusted SG&A, and Adjusted SG&A Percent of Net Revenue assist investors and analysts in comparing our operating performance across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance. Management believes these non-GAAP financial measures are useful to investors in highlighting trends in our operating performance, while other measures can differ significantly depending on long-term strategic decisions regarding capital structure, the tax jurisdictions in which we operate and capital investments. Management uses these non-GAAP financial measures to supplement GAAP measures of performance in the evaluation of the effectiveness of our business strategies, to make budgeting decisions, to establish discretionary annual incentive compensation and to compare our performance against that of other peer companies using similar measures. Management supplements GAAP results with non-GAAP financial measures to provide a more complete understanding of the factors and trends affecting the business than GAAP results alone.

    To supplement the Company's comparable store sales growth presented in accordance with GAAP, the Company provides "Adjusted Comparable Store Sales Growth," which is a non-GAAP financial measure we believe is useful because it provides timely and accurate information relating to the two core metrics of retail sales: number of transactions and value of transactions. Management uses Adjusted Comparable Store Sales Growth as the basis for key operating decisions, such as allocation of advertising to particular markets and implementation of special marketing programs. Accordingly, we believe that Adjusted Comparable Store Sales Growth provides timely and accurate information relating to the operational health and overall performance of each brand. We also believe that, for the same reasons, investors find our calculation of Adjusted Comparable Store Sales Growth to be meaningful.

    EBITDA: We define EBITDA from continuing operations as net income (loss), minus income (loss) from discontinued operations, net of tax, plus interest expense (income), net, income tax provision (benefit), and depreciation and amortization.

    Adjusted Operating Income: We define Adjusted Operating Income from continuing operations as net income (loss), minus income (loss) from discontinued operations, net of tax, plus interest expense (income), net and income tax provision (benefit), further adjusted to exclude stock-based compensation expense, (gain) loss on extinguishment of debt, asset impairment, litigation settlement, secondary offering expenses, management realignment expenses, long-term incentive plan expenses, Enterprise Resource Planning ("ERP") and Customer Relationship Management ("CRM") implementation expenses and certain other expenses.

    Adjusted Operating Margin: We define Adjusted Operating Margin from continuing operations as Adjusted Operating Income from continuing operations as a percentage of total net revenue.

    Adjusted EBITDA: We define Adjusted EBITDA from continuing operations as net income (loss), minus income (loss) from discontinued operations, net of tax, plus interest expense (income), net, income tax provision (benefit) and depreciation and amortization, further adjusted to exclude stock-based compensation expense, (gain) loss on extinguishment of debt, asset impairment, litigation settlement, secondary offering expenses, management realignment expenses, long-term incentive plan expenses, ERP and CRM implementation expenses and certain other expenses.

    Adjusted EBITDA Margin: We define Adjusted EBITDA Margin from continuing operations as Adjusted EBITDA from continuing operations as a percentage of total net revenue.

    Adjusted Diluted EPS: We define Adjusted Diluted EPS from continuing operations as diluted earnings (loss) per share, minus diluted earnings per share from discontinued operations, adjusted for the per share impact of stock-based compensation expense, (gain) loss on extinguishment of debt, asset impairment, litigation settlement, secondary offering expenses, management realignment expenses, long-term incentive plan expenses, amortization of debt discounts and deferred financing costs of our term loan borrowings, amortization of the conversion feature and deferred financing costs related to our 2025 Notes when not required under U.S. GAAP to be added back for diluted earnings (loss) per share, derivative fair value adjustments, ERP and CRM implementation expenses, certain other expenses, and related tax effects.

    Adjusted SG&A: We define Adjusted SG&A from continuing operations as SG&A from continuing operations adjusted to exclude stock-based compensation expense, litigation settlement, secondary offering expenses, management realignment expenses, long-term incentive plan expense, ERP and CRM implementation expenses, and certain other expenses.

    Adjusted SG&A Percent of Net Revenue: We define Adjusted SG&A Percent of Net Revenue from continuing operations as Adjusted SG&A from continuing operations as a percentage of total net revenue.

    Adjusted Comparable Store Sales Growth: We measure Adjusted Comparable Store Sales Growth as the increase or decrease in sales recorded by the comparable store base in any reporting period, compared to sales recorded by the comparable store base in the prior reporting period, which we calculate as follows: (i) sales are recorded on a cash basis (i.e. when the order is placed and paid for or submitted to a managed care payor, compared to when the order is delivered), utilizing cash basis point of sale information from stores; (ii) stores are added to the calculation during the 13th full fiscal month following the store's opening; (iii) closed stores are removed from the calculation for time periods that are not comparable; (iv) sales from partial months of operation are excluded when stores do not open or close on the first day of the month; and (v) when applicable, we adjust for the effect of the 53rd week. Quarterly, year-to-date and annual adjusted comparable store sales are aggregated using only sales from all whole months of operation included in both the current reporting period and the prior reporting period. When a partial month is excluded from the calculation, the corresponding month in the subsequent period is also excluded from the calculation. There may be variations in the way in which some of our competitors and other retailers calculate comparable store sales. As a result, our adjusted comparable store sales may not be comparable to similar data made available by other retailers.

    EBITDA, Adjusted Operating Income, Adjusted Operating Margin, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Diluted EPS, Adjusted SG&A, Adjusted SG&A Percent of Net Revenue and Adjusted Comparable Store Sales Growth are not recognized terms under U.S. GAAP and should not be considered as an alternative to net income or the ratio of net income to net revenue as a measure of financial performance, SG&A, the ratio of SG&A to net revenue as a measure of financial performance, cash flows provided by operating activities as a measure of liquidity, comparable store sales growth as a measure of operating performance, or any other performance measure derived in accordance with U.S. GAAP. Additionally, these measures are not intended to be a measure of free cash flow available for management's discretionary use as they do not consider certain cash requirements such as interest payments, tax payments and debt service requirements. The presentations of these measures have limitations as analytical tools and should not be considered in isolation, or as a substitute for analysis of our results as reported under U.S. GAAP. Because not all companies use identical calculations, the presentations of these measures may not be comparable to other similarly titled measures of other companies and can differ significantly from company to company.

    Please see "Reconciliation of Non-GAAP to GAAP Financial Measures" below for reconciliations of non-GAAP financial measures used in this release to their most directly comparable GAAP financial measures.

    Adjustment to Method of Tax Provision Calculation

    Prior to the second quarter of 2024, the Company's quarterly provision (benefit) for income taxes was calculated using the annualized effective tax rate method ("AETR method"), which applies an estimated annual effective tax rate to pre-tax income or loss. For the three and nine months ended September 28, 2024, the Company determined that the AETR method would not provide a reliable estimate for its tax provision (benefit) due to the fact that small changes in the Company's estimated pre-tax income or loss would result in significant changes in the estimated AETR. Accordingly, for these periods, the Company instead elected to calculate its provision (benefit) for income taxes using a discrete effective tax rate ("ETR") method.

     

    National Vision Holdings, Inc. and Subsidiaries

    Condensed Consolidated Balance Sheets (Unaudited)

     

    In Thousands, Except Par Value

    As of

    September 28, 2024

     

    As of

    December 30, 2023

    ASSETS

     

     

     

    Current assets:

     

     

     

    Cash and cash equivalents

    $

    81,154

     

     

    $

    149,896

     

    Accounts receivable, net

     

    46,795

     

     

     

    86,854

     

    Inventories, net

     

    87,593

     

     

     

    119,908

     

    Prepaid expenses and other current assets

     

    28,173

     

     

     

    40,012

     

    Total current assets

     

    243,715

     

     

     

    396,670

     

     

     

     

     

    Noncurrent assets:

     

     

     

    Property and equipment, net

     

    354,453

     

     

     

    360,187

     

    Goodwill

     

    717,544

     

     

     

    717,544

     

    Trademarks and trade names

     

    240,547

     

     

     

    240,547

     

    Other intangible assets, net

     

    8,450

     

     

     

    20,173

     

    Right of use assets

     

    419,709

     

     

     

    406,275

     

    Other assets

     

    35,711

     

     

     

    28,336

     

    Noncurrent assets of discontinued operations

     

    —

     

     

     

    2,779

     

    Total noncurrent assets

     

    1,776,414

     

     

     

    1,775,841

     

    Total assets

    $

    2,020,129

     

     

    $

    2,172,511

     

     

     

     

     

    LIABILITIES AND STOCKHOLDERS' EQUITY

     

     

     

    Current liabilities:

     

     

     

    Accounts payable

    $

    39,559

     

     

    $

    67,556

     

    Other payables and accrued expenses

     

    94,124

     

     

     

    123,288

     

    Unearned revenue

     

    38,647

     

     

     

    48,117

     

    Deferred revenue

     

    63,867

     

     

     

    62,867

     

    Current maturities of long-term debt and finance lease obligations

     

    100,993

     

     

     

    10,480

     

    Current operating lease obligations

     

    88,933

     

     

     

    85,090

     

    Current liabilities of discontinued operations

     

    —

     

     

     

    302

     

    Total current liabilities

     

    426,123

     

     

     

    397,700

     

     

     

     

     

    Noncurrent liabilities:

     

     

     

    Long-term debt and finance lease obligations, less current portion and debt discount

     

    252,848

     

     

     

    450,771

     

    Noncurrent operating lease obligations

     

    388,668

     

     

     

    376,814

     

    Deferred revenue

     

    22,704

     

     

     

    21,459

     

    Other liabilities

     

    8,826

     

     

     

    8,465

     

    Deferred income taxes, net

     

    80,963

     

     

     

    87,884

     

    Total non-current liabilities

     

    754,009

     

     

     

    945,393

     

    Commitments and contingencies

     

     

     

    Stockholders' equity:

     

     

     

    Common stock, $0.01 par value; 200,000 shares authorized; 85,334 and 84,831 shares issued as of September 28, 2024 and December 30, 2023, respectively; 78,691 and 78,311 shares outstanding as of September 28, 2024 and December 30, 2023, respectively

     

    854

     

     

     

    848

     

    Additional paid-in capital

     

    801,848

     

     

     

    788,967

     

    Accumulated other comprehensive loss

     

    —

     

     

     

    (419

    )

    Retained earnings

     

    254,708

     

     

     

    254,616

     

    Treasury stock, at cost; 6,643 and 6,520 shares as of September 28, 2024 and December 30, 2023, respectively

     

    (217,413

    )

     

     

    (214,594

    )

    Total stockholders' equity

     

    839,997

     

     

     

    829,418

     

    Total liabilities and stockholders' equity

    $

    2,020,129

     

     

    $

    2,172,511

     

     

    National Vision Holdings, Inc. and Subsidiaries

    Condensed Consolidated Statements of Operations and Comprehensive Income (Unaudited)

     

     

    Three Months Ended

     

    Nine Months Ended

    In Thousands, Except Earnings (Loss) Per Share

    September 28,

    2024

     

    September 30,

    2023

     

    September 28,

    2024

     

    September 30,

    2023

    Revenue:

     

     

     

     

     

     

     

    Net product sales

    $

    363,156

     

     

    $

    354,566

     

     

    $

    1,113,206

     

     

    $

    1,086,899

     

    Net sales of services and plans

     

    88,359

     

     

     

    84,254

     

     

     

    272,836

     

     

     

    248,519

     

    Total net revenue

     

    451,515

     

     

     

    438,820

     

     

     

    1,386,042

     

     

     

    1,335,418

     

    Costs applicable to revenue (exclusive of depreciation and amortization):

     

     

     

     

     

     

     

    Products

     

    106,392

     

     

     

    105,850

     

     

     

    330,809

     

     

     

    323,286

     

    Services and plans

     

    83,537

     

     

     

    77,979

     

     

     

    248,246

     

     

     

    226,992

     

    Total costs applicable to revenue

     

    189,929

     

     

     

    183,829

     

     

     

    579,055

     

     

     

    550,278

     

    Operating expenses:

     

     

     

     

     

     

     

    Selling, general and administrative expenses

     

    233,991

     

     

     

    227,515

     

     

     

    705,472

     

     

     

    679,115

     

    Depreciation and amortization

     

    22,690

     

     

     

    22,476

     

     

     

    68,603

     

     

     

    66,521

     

    Asset impairment

     

    13,726

     

     

     

    1,452

     

     

     

    17,701

     

     

     

    2,699

     

    Other expense (income), net

     

    —

     

     

     

    1

     

     

     

    (1

    )

     

     

    (103

    )

    Total operating expenses

     

    270,407

     

     

     

    251,444

     

     

     

    791,775

     

     

     

    748,232

     

    Income (loss) from operations

     

    (8,821

    )

     

     

    3,547

     

     

     

    15,212

     

     

     

    36,908

     

    Interest expense, net

     

    4,108

     

     

     

    3,722

     

     

     

    11,560

     

     

     

    10,425

     

    Gain on extinguishment of debt

     

    (859

    )

     

     

    —

     

     

     

    (859

    )

     

     

    —

     

    Earnings (loss) from continuing operations before income taxes

     

    (12,070

    )

     

     

    (175

    )

     

     

    4,511

     

     

     

    26,483

     

    Income tax provision (benefit)

     

    (3,630

    )

     

     

    191

     

     

     

    2,239

     

     

     

    8,198

     

    Income (loss) from continuing operations, net of tax

     

    (8,440

    )

     

     

    (366

    )

     

     

    2,272

     

     

     

    18,285

     

    Loss from discontinued operations, net of tax

     

    (28

    )

     

     

    (73,432

    )

     

     

    (2,180

    )

     

     

    (68,199

    )

    Net income (loss)

    $

    (8,468

    )

     

    $

    (73,798

    )

     

    $

    92

     

     

    $

    (49,914

    )

     

     

     

     

     

     

     

     

    Basic earnings (loss) per share:

     

     

     

     

     

     

     

    Continuing operations

    $

    (0.11

    )

     

    $

    (0.00

    )

     

    $

    0.03

     

     

    $

    0.23

     

    Discontinued operations

    $

    (0.00

    )

     

    $

    (0.94

    )

     

    $

    (0.03

    )

     

    $

    (0.87

    )

    Total

    $

    (0.11

    )

     

    $

    (0.94

    )

     

    $

    0.00

     

     

    $

    (0.64

    )

    Diluted earnings (loss) per share:

     

     

     

     

     

     

     

    Continuing operations

    $

    (0.11

    )

     

    $

    (0.00

    )

     

    $

    0.03

     

     

    $

    0.23

     

    Discontinued operations

    $

    (0.00

    )

     

    $

    (0.94

    )

     

    $

    (0.03

    )

     

    $

    (0.87

    )

    Total

    $

    (0.11

    )

     

    $

    (0.94

    )

     

    $

    0.00

     

     

    $

    (0.63

    )

     

     

     

     

     

     

     

     

    Weighted average shares outstanding:

     

     

     

     

     

     

     

    Basic

     

    78,655

     

     

     

    78,163

     

     

     

    78,538

     

     

     

    78,328

     

    Diluted

     

    78,655

     

     

     

    78,163

     

     

     

    78,747

     

     

     

    78,646

     

     

     

     

     

     

     

     

     

    Comprehensive income (loss):

     

     

     

     

     

     

     

    Net income (loss)

    $

    (8,468

    )

     

    $

    (73,798

    )

     

    $

    92

     

     

    $

    (49,914

    )

    Unrealized gain on hedge instruments

     

    64

     

     

     

    255

     

     

     

    548

     

     

     

    763

     

    Tax provision of unrealized gain on hedge instruments

     

    —

     

     

     

    65

     

     

     

    128

     

     

     

    195

     

    Comprehensive income (loss)

    $

    (8,404

    )

     

    $

    (73,608

    )

     

    $

    512

     

     

    $

    (49,346

    )

     

    Note: Diluted EPS related to the 2025 Notes is calculated using the if-converted method. The 2025 Notes were anti-dilutive for all periods disclosed above and excluded from the computation of the weighted average shares for Diluted EPS. Some totals in the table above may not foot due to rounding differences.

     

    National Vision Holdings, Inc. and Subsidiaries

    Condensed Consolidated Statements of Cash Flows (Unaudited)

     

     

    Nine Months Ended

    In Thousands

    September 28,

    2024

     

    September 30,

    2023

    Cash flows from operating activities:

     

     

     

    Net income (loss)

    $

    92

     

     

    $

    (49,914

    )

    Adjustments to reconcile net income to net cash provided by operating activities:

     

     

     

    Depreciation and amortization

     

    69,934

     

     

     

    74,149

     

    Amortization of debt discount and deferred financing costs

     

    1,740

     

     

     

    2,604

     

    Amortization of cloud computing implementation costs

     

    3,842

     

     

     

    2,028

     

    Asset impairment

     

    17,915

     

     

     

    82,114

     

    Deferred income tax expense (benefit)

     

    (6,921

    )

     

     

    (413

    )

    Stock-based compensation expense

     

    11,778

     

     

     

    15,040

     

    Losses (gains) on change in fair value of derivatives

     

    (34

    )

     

     

    (1,942

    )

    Inventory adjustments

     

    3,618

     

     

     

    2,886

     

    Other

     

    (283

    )

     

     

    2,283

     

    Changes in operating assets and liabilities:

     

     

     

    Accounts receivable

     

    39,705

     

     

     

    2,743

     

    Inventories

     

    28,697

     

     

     

    (311

    )

    Operating lease right of use assets and lease liabilities

     

    (1,692

    )

     

     

    59

     

    Other assets

     

    2,082

     

     

     

    2,769

     

    Accounts payable

     

    (27,997

    )

     

     

    (2,394

    )

    Deferred and unearned revenue

     

    (7,225

    )

     

     

    1,218

     

    Other liabilities

     

    (31,884

    )

     

     

    20,353

     

    Net cash provided by operating activities

     

    103,367

     

     

     

    153,272

     

    Cash flows from investing activities:

     

     

     

    Purchase of property and equipment

     

    (63,485

    )

     

     

    (81,965

    )

    Other

     

    1,117

     

     

     

    (614

    )

    Net cash used for investing activities

     

    (62,368

    )

     

     

    (82,579

    )

    Cash flows from financing activities:

     

     

     

    Repayments on long-term debt

     

    (218,751

    )

     

     

    (1,875

    )

    Proceeds from issuance of long-term debt

     

    115,000

     

     

     

    —

     

    Proceeds from issuance of common stock

     

    1,201

     

     

     

    1,326

     

    Purchase of treasury stock

     

    (2,819

    )

     

     

    (27,662

    )

    Payments of debt issuance costs

     

    (1,703

    )

     

     

    (2,869

    )

    Payments on finance lease obligations

     

    (2,279

    )

     

     

    (3,085

    )

    Net cash used for financing activities

     

    (109,351

    )

     

     

    (34,165

    )

    Net change in cash, cash equivalents and restricted cash

     

    (68,352

    )

     

     

    36,528

     

    Cash, cash equivalents and restricted cash, beginning of year

     

    151,027

     

     

     

    230,624

     

    Cash, cash equivalents and restricted cash, end of period

    $

    82,675

     

     

    $

    267,152

     

     

     

     

     

    Supplemental cash flow disclosure information:

     

     

     

    Cash paid for interest

    $

    7,600

     

     

    $

    6,378

     

    Cash paid for taxes

    $

    5,996

     

     

    $

    6,338

     

    Capital expenditures accrued at the end of the period

    $

    9,063

     

     

    $

    8,969

     

     

    National Vision Holdings, Inc. and Subsidiaries

    Reconciliation of Non-GAAP to GAAP Financial Measures (Unaudited) 

     

    Reconciliation of Adjusted Operating Income from Continuing Operations to Net Income (Loss)

     

    Three Months Ended

     

    Nine Months Ended

    In thousands

    September 28,

    2024

     

    September 30,

    2023

     

    September 28,

    2024

     

    September 30,

    2023

    Net income (loss)

    $

    (8,468

    )

     

    $

    (73,798

    )

     

    $

    92

     

     

    $

    (49,914

    )

    Income (loss) from discontinued operations, net of tax

     

    (28

    )

     

     

    (73,432

    )

     

     

    (2,180

    )

     

     

    (68,199

    )

    Income (loss) from continuing operations, net of tax

     

    (8,440

    )

     

     

    (366

    )

     

     

    2,272

     

     

     

    18,285

     

    Interest expense, net

     

    4,108

     

     

     

    3,722

     

     

     

    11,560

     

     

     

    10,425

     

    Income tax provision (benefit)

     

    (3,630

    )

     

     

    191

     

     

     

    2,239

     

     

     

    8,198

     

    Stock-based compensation expense (a)

     

    4,615

     

     

     

    5,099

     

     

     

    11,779

     

     

     

    14,320

     

    Gain on extinguishment of debt (b)

     

    (859

    )

     

     

    —

     

     

     

    (859

    )

     

     

    —

     

    Asset impairment (c)

     

    13,726

     

     

     

    1,452

     

     

     

    17,701

     

     

     

    2,699

     

    Litigation settlement (d)

     

    —

     

     

     

    —

     

     

     

    4,450

     

     

     

    —

     

    ERP and CRM implementation expenses (g)

     

    1,804

     

     

     

    173

     

     

     

    4,461

     

     

     

    173

     

    Other (h)

     

    2,970

     

     

     

    1,429

     

     

     

    8,658

     

     

     

    2,534

     

    Adjusted Operating Income from continuing operations

    $

    14,294

     

     

    $

    11,700

     

     

    $

    62,261

     

     

    $

    56,634

     

     

     

     

     

     

     

     

     

    Income (loss) from continuing operations, net of tax margin

     

    (1.9

    )%

     

     

    (0.1

    )%

     

     

    0.2

    %

     

     

    1.4

    %

    Adjusted Operating Margin from continuing operations

     

    3.2

    %

     

     

    2.7

    %

     

     

    4.5

    %

     

     

    4.2

    %

     

     

     

     

     

     

     

     

    Note: Percentages reflect line item as a percentage of total net revenue, adjusted for rounding.

     

    Reconciliation of EBITDA from Continuing Operations and Adjusted EBITDA from Continuing Operations to Net Income (Loss)

     

    Three Months Ended

     

    Nine Months Ended

    In thousands

    September 28,

    2024

     

    September 30,

    2023

     

    September 28,

    2024

     

    September 30,

    2023

    Net income (loss)

    $

    (8,468

    )

     

    $

    (73,798

    )

     

    $

    92

     

     

    $

    (49,914

    )

    Income (loss) from discontinued operations, net of tax

     

    (28

    )

     

     

    (73,432

    )

     

     

    (2,180

    )

     

     

    (68,199

    )

    Income (loss) from continuing operations, net of tax

     

    (8,440

    )

     

     

    (366

    )

     

     

    2,272

     

     

     

    18,285

     

    Interest expense, net

     

    4,108

     

     

     

    3,722

     

     

     

    11,560

     

     

     

    10,425

     

    Income tax provision (benefit)

     

    (3,630

    )

     

     

    191

     

     

     

    2,239

     

     

     

    8,198

     

    Depreciation and amortization

     

    22,690

     

     

     

    22,476

     

     

     

    68,603

     

     

     

    66,521

     

    EBITDA from continuing operations

     

    14,728

     

     

     

    26,023

     

     

     

    84,674

     

     

     

    103,429

     

     

     

     

     

     

     

     

     

    Stock-based compensation expense (a)

     

    4,615

     

     

     

    5,099

     

     

     

    11,779

     

     

     

    14,320

     

    Gain on extinguishment of debt (b)

     

    (859

    )

     

     

    —

     

     

     

    (859

    )

     

     

    —

     

    Asset impairment (c)

     

    13,726

     

     

     

    1,452

     

     

     

    17,701

     

     

     

    2,699

     

    Litigation settlement (d)

     

    —

     

     

     

    —

     

     

     

    4,450

     

     

     

    —

     

    ERP and CRM implementation expenses (g)

     

    1,804

     

     

     

    173

     

     

     

    4,461

     

     

     

    173

     

    Other (h)

     

    2,589

     

     

     

    1,048

     

     

     

    7,514

     

     

     

    1,390

     

    Adjusted EBITDA from continuing operations

    $

    36,603

     

     

    $

    33,795

     

     

    $

    129,720

     

     

    $

    122,011

     

     

     

     

     

     

     

     

     

    Income (loss) from continuing operations, net of tax margin

     

    (1.9

    )%

     

     

    (0.1

    )%

     

     

    0.2

    %

     

     

    1.4

    %

    Adjusted EBITDA Margin from continuing operations

     

    8.1

    %

     

     

    7.7

    %

     

     

    9.4

    %

     

     

    9.1

    %

     

     

     

     

     

     

     

     

    Note: Percentages reflect line item as a percentage of total net revenue, adjusted for rounding.

     

    Reconciliation of Adjusted Diluted EPS from Continuing Operations to Diluted EPS

     

    Three Months Ended

     

    Nine Months Ended

    Shares in thousands, except per share amounts

    September 28,

    2024

     

    September 30,

    2023

     

    September 28,

    2024

     

    September 30,

    2023

    Diluted EPS

    $

    (0.11

    )

     

    $

    (0.94

    )

     

    $

    0.00

     

     

    $

    (0.63

    )

    Diluted EPS from discontinued operations

     

    (0.00

    )

     

     

    (0.94

    )

     

     

    (0.03

    )

     

     

    (0.87

    )

    Diluted EPS from continuing operations

    $

    (0.11

    )

     

    $

    (0.00

    )

     

    $

    0.03

     

     

    $

    0.23

     

    Stock-based compensation expense (a)

     

    0.06

     

     

     

    0.07

     

     

     

    0.15

     

     

     

    0.18

     

    Gain on extinguishment of debt (b)

     

    (0.01

    )

     

     

    —

     

     

     

    (0.01

    )

     

     

    —

     

    Asset impairment (c)

     

    0.17

     

     

     

    0.02

     

     

     

    0.22

     

     

     

    0.03

     

    Litigation settlement (d)

     

    —

     

     

     

    —

     

     

     

    0.06

     

     

     

    —

     

    Amortization of debt discount and deferred financing costs (e)

     

    0.01

     

     

     

    0.01

     

     

     

    0.02

     

     

     

    0.03

     

    Derivatives fair value adjustments (f)

     

    0.01

     

     

     

    0.03

     

     

     

    0.08

     

     

     

    0.08

     

    ERP and CRM implementation expenses (g)

     

    0.02

     

     

     

    0.00

     

     

     

    0.06

     

     

     

    0.00

     

    Other (h)

     

    0.04

     

     

     

    0.02

     

     

     

    0.11

     

     

     

    0.03

     

    Tax effects (i)

     

    (0.07

    )

     

     

    (0.04

    )

     

     

    (0.16

    )

     

     

    (0.08

    )

    Adjusted Diluted EPS from continuing operations

    $

    0.12

     

     

    $

    0.11

     

     

    $

    0.56

     

     

    $

    0.51

     

     

     

     

     

     

     

     

     

    Weighted average diluted shares outstanding

     

    78,655

     

     

     

    78,163

     

     

     

    78,747

     

     

     

    78,646

     

     

     

     

     

     

     

     

     

    Note: Some of the totals in the table above do not foot due to rounding differences.

    Reconciliation of Adjusted SG&A from Continuing Operations to SG&A from Continuing Operations

     

    Three Months Ended

     

    Nine Months Ended

    In thousands

    September 28,

    2024

     

    September 30,

    2023

     

    September 28,

    2024

     

    September 30,

    2023

    SG&A from continuing operations

    $

    233,991

     

     

    $

    227,515

     

     

    $

    705,472

     

     

    $

    679,115

     

    Stock-based compensation expense (a)

     

    4,615

     

     

     

    5,099

     

     

     

    11,779

     

     

     

    14,320

     

    Litigation settlement (d)

     

    —

     

     

     

    —

     

     

     

    4,450

     

     

     

    —

     

    ERP and CRM implementation expenses (g)

     

    1,804

     

     

     

    173

     

     

     

    4,461

     

     

     

    173

     

    Other (h)

     

    2,532

     

     

     

    1,048

     

     

     

    7,457

     

     

     

    1,394

     

    Adjusted SG&A from continuing operations

    $

    225,040

     

     

    $

    221,195

     

     

    $

    677,325

     

     

    $

    663,228

     

     

     

     

     

     

     

     

     

    SG&A from continuing operations Percent of Net Revenue

     

    51.8

    %

     

     

    51.8

    %

     

     

    50.9

    %

     

     

    50.9

    %

    Adjusted SG&A from continuing operations Percent of Net Revenue

     

    49.8

    %

     

     

    50.4

    %

     

     

    48.9

    %

     

     

    49.7

    %

     

    Note: Percentages reflect line item as a percentage of total net revenue.

    (a) Non-cash charges related to stock-based compensation programs, which vary from period to period depending on the timing of awards and performance vesting conditions.
    (b) For the three and nine months ended September 28, 2024, reflects the gain on extinguishment related to the repurchase of $217.7 million of the 2025 Notes on August 12, 2024.
    (c) Reflects write-off related to non-cash impairment charges of long-lived assets, primarily impairment of Fred Meyer contracts and relationships intangible asset of $10.5 million for the three and nine months ended September 28, 2024, and impairment of property, equipment and lease-related assets on closed or underperforming stores and certain store closure decisions made as part of the Company's store optimization review in the current period.
    (d) Expenses associated with settlement of certain litigation.
    (e) Amortization of deferred financing costs and other non-cash charges related to our debt. We adjust for amortization of deferred financing costs related to the 2025 Notes only when adjustment for these costs is not required in the calculation of diluted earnings per share under U.S. GAAP.
    (f) The adjustments for the derivative fair value (gains) and losses have the effect of adjusting the (gain) or loss for changes in the fair value of derivative instruments and amortization of AOCL for derivatives not designated as accounting hedges. This results in reflecting derivative (gains) and losses within Adjusted Diluted EPS during the period the derivative is settled.
    (g) Costs related to the Company's ERP and CRM implementation.
    (h) Other adjustments include amounts that management believes are not representative of our operating performance (amounts in brackets represent reductions in Adjusted Operating Income, Adjusted Diluted EPS, Adjusted EBITDA and Adjusted SG&A), which are primarily related to costs associated with the digitization of paper-based records of $1.5 million and $5.7 million for the three and nine months ended September 28, 2024, respectively, costs associated with the store fleet review of $1.1 million for the three and nine months ended September 28, 2024, and other expenses and adjustments. Other adjustments for both Adjusted Operating Income and Adjusted Diluted EPS include amortization of the increase in carrying values of finite-lived intangible assets resulting from the application of purchase accounting following the acquisition of the Company by affiliates of KKR & Co. Inc. Adjusted Diluted EPS is also adjusted to include debt issuance costs. Other adjustments for Adjusted SG&A exclude gains and losses on other investments and optometrist-related store optimization costs.
    (i) Represents the income tax effect of the total adjustments at our combined statutory federal and state income tax rates, including tax expense (benefit) from stock-based compensation.
     

    Reconciliation of Adjusted Comparable Store Sales Growth from Continuing Operations to Total Comparable Store Sales Growth from Continuing Operations

     

    Comparable store sales growth from continuing operations (a)

     

    Three Months

    Ended

    September 28, 2024

     

    Three Months

    Ended

    September 30, 2023

     

    Nine Months

    Ended

    September 28, 2024

     

    Nine Months

    Ended

    September 30, 2023

     

    2024 Outlook (b)

    Owned & Host segment

     

     

     

     

     

     

     

     

     

    America's Best

    1.2

     %

     

    5.7

     %

     

    1.7

     %

     

    3.0

     %

     

     

    Eyeglass World

    (0.9

    )%

     

    (1.2

    )%

     

    (2.3

    )%

     

    (1.7

    )%

     

     

    Military

    (0.6

    )%

     

    3.8

     %

     

    (0.7

    )%

     

    2.3

     %

     

     

    Fred Meyer

    (7.3

    )%

     

    (3.7

    )%

     

    (5.3

    )%

     

    (5.9

    )%

     

     

     

     

     

     

     

     

     

     

     

     

    Total comparable store sales growth from continuing operations

    1.4

     %

     

    4.1

     %

     

    1.7

     %

     

    2.4

     %

     

    1.0% - 2.0%

    Adjustments for effects of: (b)

     

     

     

     

     

     

     

     

     

    Unearned & deferred revenue

    (0.5

    )%

     

    0.6

     %

     

    (0.5

    )%

     

    (0.1

    )%

     

     

    Adjusted Comparable Store Sales Growth from continuing operations

    0.9

     %

     

    4.7

     %

     

    1.2

     %

     

    2.3

     %

     

    0.5% - 1.5%

    (a) Total comparable store sales from continuing operations is calculated based on consolidated net revenue from continuing operations excluding the impact of (i) Corporate/Other segment net revenue, (ii) sales from stores opened less than 13 months, (iii) stores closed in the periods presented, (iv) sales from partial months of operation when stores do not open or close on the first day of the month and (v) if applicable, the impact of a 53rd week in a fiscal year. Brand-level comparable store sales growth is calculated based on cash basis revenues consistent with what the CODM reviews, and consistent with reportable segment revenues presented in Note 12. "Segment Reporting" in our unaudited condensed consolidated financial statements included in Part I. Item 1. in our Quarterly Report on Form 10-Q for the period ended September 28, 2024.
     
    (b) Adjusted Comparable Store Sales Growth from continuing operations includes the effect of deferred and unearned revenue as if such revenues were earned at the point of sale, resulting in the changes from total comparable store sales growth from continuing operations based on consolidated net revenue from continuing operations; with respect to the Company's 2024 Outlook, Adjusted Comparable Store Sales Growth includes an estimated 0.5% decrease for the effect of deferred and unearned revenue as if such revenues were earned at the point of sale.

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20241106071372/en/

    Get the next $EYE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EYE

    DatePrice TargetRatingAnalyst
    5/9/2025$21.00Neutral → Buy
    Citigroup
    5/7/2025Underperform → Buy
    BofA Securities
    10/17/2023$25.00 → $16.00Buy → Neutral
    Goldman
    7/27/2023$28.00 → $22.00Buy → Neutral
    Citigroup
    7/27/2023$30.00 → $21.00Overweight → Equal Weight
    Wells Fargo
    5/2/2023Overweight → Equal Weight
    Barclays
    3/31/2023$23.00Hold → Buy
    Loop Capital
    1/17/2023Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $EYE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • National Vision Holdings, Inc. Reports First Quarter 2025 Financial Results

      Successful Execution of New Transformation Initiatives and Cost Reduction Actions Delivered Strong First Quarter First quarter 2025 highlights compared to Q1 2024: Net revenue from continuing operations of $510.3 million, an increase of 5.7% Comparable store sales growth of 4.1% and Adjusted Comparable Store Sales Growth of 5.5% represented the 9th consecutive quarter of positive growth Income from continuing operations of $14.2 million, Diluted EPS from continuing operations of $0.18 Adjusted Operating Income from continuing operations of $41.3 million Adjusted Diluted EPS from continuing operations of $0.34 Raises fiscal 2025 outlook National Vision Holdings, Inc. (NASDAQ:E

      5/7/25 6:00:00 AM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • National Vision Appoints Alex Wilkes as CEO

      Reade Fahs to Assume Executive Chairman Position Transition Effective August 1, 2025 National Vision Holdings, Inc. (NASDAQ:EYE) ("National Vision" or the "Company") today announced that its Board of Directors has appointed Alex Wilkes as the Company's next Chief Executive Officer, effective August 1, 2025, and he will join the Company's Board at that time. Mr. Wilkes succeeds Reade Fahs who will assume the role of Executive Chairman of the Board. Mr. Fahs will continue to work closely with Mr. Wilkes, ensuring a smooth transition. "National Vision has been on a journey of significant transformation for the past few years, and today I am pleased to announce the next chapter in that tran

      4/29/25 6:00:00 AM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • National Vision Holdings, Inc. Announces First Quarter 2025 Earnings Release and Conference Call

      National Vision Holdings, Inc. (NASDAQ:EYE) ("National Vision" or the "Company") will report its first quarter 2025 financial results before the market opens on Wednesday, May 7, 2025, and will host a conference call at 8:30 a.m. Eastern Time. To pre-register for the conference call and obtain a dial-in number and passcode, please refer to the "Investors" section of the Company's website at www.nationalvision.com/investors. A live audio webcast of the conference call, together with related materials, will be available online in the "Investors" section of the Company's website. A replay of the audio webcast will be available shortly after the broadcast. About National Vision Holdings, Inc.

      4/24/25 8:00:00 AM ET
      $EYE
      Ophthalmic Goods
      Health Care

    $EYE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • National Vision upgraded by Citigroup with a new price target

      Citigroup upgraded National Vision from Neutral to Buy and set a new price target of $21.00

      5/9/25 8:39:42 AM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • National Vision upgraded by BofA Securities

      BofA Securities upgraded National Vision from Underperform to Buy

      5/7/25 2:46:43 PM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • National Vision downgraded by Goldman with a new price target

      Goldman downgraded National Vision from Buy to Neutral and set a new price target of $16.00 from $25.00 previously

      10/17/23 7:19:16 AM ET
      $EYE
      Ophthalmic Goods
      Health Care

    $EYE
    SEC Filings

    See more
    • SEC Form 10-Q filed by National Vision Holdings Inc.

      10-Q - National Vision Holdings, Inc. (0001710155) (Filer)

      5/8/25 8:36:28 AM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • National Vision Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - National Vision Holdings, Inc. (0001710155) (Filer)

      5/7/25 6:05:18 AM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • SEC Form DEF 14A filed by National Vision Holdings Inc.

      DEF 14A - National Vision Holdings, Inc. (0001710155) (Filer)

      4/29/25 6:22:58 AM ET
      $EYE
      Ophthalmic Goods
      Health Care

    $EYE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by National Vision Holdings Inc.

      SC 13G/A - National Vision Holdings, Inc. (0001710155) (Subject)

      11/14/24 12:33:08 PM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • Amendment: SEC Form SC 13G/A filed by National Vision Holdings Inc.

      SC 13G/A - National Vision Holdings, Inc. (0001710155) (Subject)

      11/12/24 4:45:48 PM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • Amendment: SEC Form SC 13G/A filed by National Vision Holdings Inc.

      SC 13G/A - National Vision Holdings, Inc. (0001710155) (Subject)

      11/4/24 1:18:26 PM ET
      $EYE
      Ophthalmic Goods
      Health Care

    $EYE
    Financials

    Live finance-specific insights

    See more
    • National Vision Holdings, Inc. Reports First Quarter 2025 Financial Results

      Successful Execution of New Transformation Initiatives and Cost Reduction Actions Delivered Strong First Quarter First quarter 2025 highlights compared to Q1 2024: Net revenue from continuing operations of $510.3 million, an increase of 5.7% Comparable store sales growth of 4.1% and Adjusted Comparable Store Sales Growth of 5.5% represented the 9th consecutive quarter of positive growth Income from continuing operations of $14.2 million, Diluted EPS from continuing operations of $0.18 Adjusted Operating Income from continuing operations of $41.3 million Adjusted Diluted EPS from continuing operations of $0.34 Raises fiscal 2025 outlook National Vision Holdings, Inc. (NASDAQ:E

      5/7/25 6:00:00 AM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • National Vision Holdings, Inc. Announces First Quarter 2025 Earnings Release and Conference Call

      National Vision Holdings, Inc. (NASDAQ:EYE) ("National Vision" or the "Company") will report its first quarter 2025 financial results before the market opens on Wednesday, May 7, 2025, and will host a conference call at 8:30 a.m. Eastern Time. To pre-register for the conference call and obtain a dial-in number and passcode, please refer to the "Investors" section of the Company's website at www.nationalvision.com/investors. A live audio webcast of the conference call, together with related materials, will be available online in the "Investors" section of the Company's website. A replay of the audio webcast will be available shortly after the broadcast. About National Vision Holdings, Inc.

      4/24/25 8:00:00 AM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • National Vision Holdings, Inc. Reports Fourth Quarter and Fiscal 2024 Financial Results

      Strong Fourth Quarter Results Reflect Successful Execution on Store-Level Transformation Initiatives Introduced Targeted Initiatives to Broaden Appeal and Expand Customer Base Actions Taken to Reduce Costs and Strengthen Profitability Fourth quarter 2024 highlights: Net revenue from continuing operations of $437.3 million, an increase of 3.9% as compared to Q4 2023 Comparable store sales growth of 2.6% and Adjusted Comparable Store Sales Growth of 1.5% as compared to Q4 2023 Net loss from continuing operations of $(29.4) million, Diluted EPS from continuing operations of $(0.37) Adjusted Operating Income from continuing operations increased to $3.2 million from $(2.7) mill

      2/26/25 6:00:00 AM ET
      $EYE
      Ophthalmic Goods
      Health Care

    $EYE
    Leadership Updates

    Live Leadership Updates

    See more
    • National Vision Appoints Alex Wilkes as CEO

      Reade Fahs to Assume Executive Chairman Position Transition Effective August 1, 2025 National Vision Holdings, Inc. (NASDAQ:EYE) ("National Vision" or the "Company") today announced that its Board of Directors has appointed Alex Wilkes as the Company's next Chief Executive Officer, effective August 1, 2025, and he will join the Company's Board at that time. Mr. Wilkes succeeds Reade Fahs who will assume the role of Executive Chairman of the Board. Mr. Fahs will continue to work closely with Mr. Wilkes, ensuring a smooth transition. "National Vision has been on a journey of significant transformation for the past few years, and today I am pleased to announce the next chapter in that tran

      4/29/25 6:00:00 AM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • National Vision Appoints Jim McGrann and Michael Nicholson to Board of Directors

      Enters into Cooperation Agreement with Engine Capital National Vision Holdings, Inc. (NASDAQ:EYE) ("National Vision" or the "Company") today announced the appointment of two new independent directors, Jim McGrann and Michael Nicholson to its Board of Directors (the "Board"), effective March 17, 2025. Mr. McGrann will serve on the Board's Compensation Committee and Mr. Nicholson will serve on the Board's Audit Committee and Nominating and Corporate Governance Committee. With the addition of Messrs. McGrann and Nicholson, the Board will expand from 9 to 11 members. The Board has also formed an Advisory Committee that will help oversee National Vision's ongoing transformation initiatives with

      3/17/25 4:05:00 PM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • National Vision Appoints Christopher Laden as Chief Financial Officer

      National Vision Holdings, Inc. (NASDAQ:EYE) ("National Vision" or the "Company") today announced the appointment of Christopher Laden as Chief Financial Officer, effective March 31, 2025. He will succeed Melissa Rasmussen who, as previously announced, will step down from the Company, effective March 3, 2025. "We are thrilled to welcome Chris to National Vision. He has a proven track record of successfully developing finance organizations into strong cross-functional business partners by focusing on accountability, employee development, and driving efficiencies through the use of digitization. His experience in both the service and optical industries will be instrumental as we move forward

      2/26/25 5:59:00 AM ET
      $EYE
      Ophthalmic Goods
      Health Care

    $EYE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP, Chief Technology Officer Acharya Ravi sold $225,060 worth of shares (12,000 units at $18.75), decreasing direct ownership by 51% to 11,700 units (SEC Form 4)

      4 - National Vision Holdings, Inc. (0001710155) (Issuer)

      5/14/25 4:37:10 PM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • Chief Legal & Strategy Officer Brandman Jared converted options into 1,889 shares and covered exercise/tax liability with 562 shares, increasing direct ownership by 3% to 44,705 units (SEC Form 4)

      4 - National Vision Holdings, Inc. (0001710155) (Issuer)

      4/30/25 4:27:11 PM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • Chief Brand & Mktg Officer Vandette Joseph converted options into 1,831 shares and covered exercise/tax liability with 545 shares, increasing direct ownership by 9% to 15,940 units (SEC Form 4)

      4 - National Vision Holdings, Inc. (0001710155) (Issuer)

      4/14/25 4:43:08 PM ET
      $EYE
      Ophthalmic Goods
      Health Care

    $EYE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Peeler D Randolph bought $264,200 worth of shares (25,000 units at $10.57) (SEC Form 4)

      4 - National Vision Holdings, Inc. (0001710155) (Issuer)

      8/14/24 4:27:52 PM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • Director Hepner Virginia A bought $10,365 worth of shares (1,000 units at $10.37), increasing direct ownership by 3% to 36,635 units (SEC Form 4)

      4 - National Vision Holdings, Inc. (0001710155) (Issuer)

      8/14/24 4:26:51 PM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • Fahs L Reade bought $299,200 worth of shares (20,000 units at $14.96), increasing direct ownership by 3% to 633,097 units (SEC Form 4)

      4 - National Vision Holdings, Inc. (0001710155) (Issuer)

      5/14/24 8:01:46 AM ET
      $EYE
      Ophthalmic Goods
      Health Care